© The American Society of Gene Therapy commentary species, probably as a result of
differential expression of receptors across species. For instance, direct administration of …

Gray et al. also report that very low neutralizing antibody titers in the blood of NHPs blocked
the otherwise impressive transduction of glial cells throughout the central nervous system. 4 …

Introduction: Straightforward studies compared adeno-associated virus (AAV) serotypes to
determine the most appropriate one for robust expression in the CNS. AAV9 was efficient …

The identification of the most efficient method for whole central nervous system targeting that
is translatable to humans and the safest route of adeno-associated virus (AAV) …

A pilot study in nonhuman primates was conducted, in which two Rhesus macaques
received bilateral parenchymal infusions of adeno-associated virus serotype 9 encoding …

There is strong interest in developing practical strategies for gene delivery to the central
nervous system (CNS). Direct delivery into the brain or spinal cord is highly invasive as well …

Other labs have previously reported the ability of adeno-associated virus serotype 9 (AAV9)
to cross the blood-brain barrier (BBB). In this report, we carefully characterized variables that …

Adeno-associated virus serotype 9 (AAV9) has shown remarkable efficiency in transducing
organs in vivo including the heart, liver, and brain. 1–6 Recently, AAV9 has gained renewed …

Recombinant adeno-associated viral (AAV) vectors have advanced to the vanguard of gene
therapy. Numerous naturally occurring serotypes have been used to target cells in various …

Adeno-associated viral (AAV) vectors have shown promise as a platform for gene therapy of
neurological disorders. Achieving global gene delivery to the central nervous system (CNS) …